What is the goal of the study?
HVTN 505 is a Phase II clinical study examining a combination of two investigational HIV vaccines. The purpose of the study is to see if the vaccine regimen reduces the amount of HIV in the blood of people who later become infected with HIV. The study also aims to provide additional information about the good safety record of the vaccine regimen.
What is the study regimen?
The HVTN 505 vaccine regimen consists of two vaccines:
Study participants cannot become infected with HIV from the vaccines. Neither of the two vaccines contains HIV and neither vaccine can infect study participants with the virus. Both vaccines have been found safe when tested in animals and when previously tested in hundreds of people in clinical trials.
What does study participation involve?
Study participation involves going through an informed consent process, eligibility screening, study enrollment with vaccination, and follow-up visits. Financial compensation is provided for study participation.
Who can volunteer to participate?
You may be eligible to participate in this study if you meet the following criteria:
See a full list of eligibility criteria to participate in this study.
Where is the study taking place?
Study visits are conducted at the Vaccine Research Center at the National Institutes of Health Clinical Center in Bethesda, Maryland.
How do I volunteer to participate?
What if I don’t live near the NIH Clinical Center?
See a full list of study site contacts and locations for this study.
How can I get more information about the HVTN 505 study?
See the study bulletin and www.hopetakesaction.org.
Last Updated December 02, 2010
Last Reviewed September 20, 2010